FluMist manufacturing facility cited
Executive Summary
FDA issues MedImmune a warning letter citing the company for manufacturing deficiencies at its Liverpool, U.K. facility, including failure to implement a program to control microbial contamination of eggs used to make FluMist. FDA does not expect lower availability of the flu vaccine for the 2007-2008 flu season, unlike the 2004-2005 season when GMP violations by Chiron caused a shortage...
You may also be interested in...
FDA Relaxes Restrictions on Live Vaccine Processing
Manufacturers of live vaccines such as those for influenza will soon be able to rely solely on process controls and, where necessary, process containment, to prevent cross-contamination of live vaccine organisms, under a recent direct final rule by FDA
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.